FDA
- Status: approved
🇺🇸 glicazide in United States
59 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 27 March 2025 – 27 March 2026
- Total reports: 59
Most-reported reactions
- Acute Kidney Injury — 9 reports (15.25%)
- Decreased Appetite — 6 reports (10.17%)
- Fournier^S Gangrene — 6 reports (10.17%)
- Malaise — 6 reports (10.17%)
- Metabolic Acidosis — 6 reports (10.17%)
- Nausea — 6 reports (10.17%)
- Blood Glucose Increased — 5 reports (8.47%)
- Confusional State — 5 reports (8.47%)
- Drug Ineffective — 5 reports (8.47%)
- Dyspnoea — 5 reports (8.47%)
Other Other approved in United States
Frequently asked questions
Is glicazide approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for glicazide in United States?
Novo Nordisk A/S is the originator. The local marketing authorisation holder may differ — check the official source linked above.